Settle down guys - here are the facts !! ........
Prima has done 5 phase I studys on CVac until they found what worked. Then they completed a phase II study and are doing a second phase IIb for a ?Potency Assay? and to comply with US FDA IND. The phase III will provide ?statistical significance for US FDA and EU EMA approval?
On Abagovomab see this news
http://www.medpagetoday.com/MeetingCoverage/ASCO/26956
For Abagovomab mode of delivery(CA-125 monoclonal antibody) mimicked the previously failed phase III study of Oregovomab in 2009
See article on Oregovomab
http://jco.ascopubs.org/content/27/3/418.full
Notice the author is Dr Jonathan Berek on why Oregovomab failed. The expert call from Dr Berek on why CVac is a winner
Listen to this opinion on
http://www.investorcalendar.com/IC/CEPage.asp?ID=163542
- Forums
- ASX - By Stock
- IMM
- abagovomab vs oregovomab - facts ...
abagovomab vs oregovomab - facts ...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M |
Open | High | Low | Value | Volume |
32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 53192 | 29.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.5¢ | 41048 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 51196 | 0.295 |
9 | 230902 | 0.290 |
5 | 74631 | 0.285 |
22 | 480847 | 0.280 |
4 | 114783 | 0.275 |
Price($) | Vol. | No. |
---|---|---|
0.305 | 41048 | 1 |
0.310 | 25000 | 2 |
0.315 | 10525 | 1 |
0.320 | 76654 | 4 |
0.325 | 30000 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online